Menu
TREATMENTS
Studies and data about therapeutic strategieTREATMENTS
Antiviral drugs & Antimalarian
 |
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 |
|---|
|
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 - ScienceDirect |
|---|
|
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019:a retrospective cohort study |
|---|
|
Challenges and countermeasures for organ donation during the SARS-CoV-2 epidemic: the experience of Sichuan Provincial... |
|---|
|
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta... |
|---|
|
Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically... |
|---|
|
Coronavirus epidemic: preparing for extracorporeal organ support in intensive care |
|---|
|
Critical care crisis and some recommendations during the COVID-19 epidemic in China |
|---|
|
Critical care management of adults with community-acquired severe respiratory viral infection |
|---|
|
Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19) |
|---|
|
Drug treatment options for the 2019-new coronavirus (2019-nCoV) |
|---|
|
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019 |
|---|
|
Formal guidelines: management of acute respiratory distress syndrome |
|---|
|
Guidelines on the management of acute respiratory distress syndrome |
|---|
|
How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital |
|---|
|
How to face the novel coronavirus infection during the 2019–2020 epidemic: the experience of Sichuan Provincial... |
|---|
|
Hydroxyzine and QTc interval: drugs without sin cast the first stone! |
|---|
|
Intensive care during the coronavirus epidemic |
|---|
|
Novel coronavirus infection during the 2019–2020 epidemic: preparing intensive care units—the experience in Sichuan... |
|---|
|
Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may... |
|---|
|
pH Dependent Differential Binding Behavior of Prtotease Inhibitor Molecular Drugs for SARS-COV-2 |
|---|
|
Pneumonia, BiPAP, secretions, and HFNC: New lessons from FLORALI |
|---|
|
Potential interventions for novel coronavirus in China: A systematic review |
|---|
|
Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking[v2] |
|---|
|
Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation |
|---|
|
Reducing mortality from 2019-nCoV: host-directed therapies should be an option |
|---|
|
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro |
|---|
|
Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists |
|---|
|
Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) |
|---|
|
Thalidomide Combined with Low-dose Glucocorticoid in the Treatment of COVID-19 Pneumonia[v1] | Preprints |
|---|
|
Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched... |
|---|
|
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate... |
|---|